A Phase 4 interventional study of Peginterferon alfa-2a and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 21 sites in Austria. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-08-04.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 8th largest by enrollment, is one of 12 that started in 2003, is one of 48 in phase 4, and was the 77th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 20 · Phase 4 48
First in 2000; this study’s year is marked. 12 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 737 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 129 across the 83 interventional studies. Of the 75 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 83 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2003, is one of 29 in phase 4, and was the 79th registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare the efficacy and safety of 2 different treatment durations of peginterferon alfa-2a (Pegasys) plus ribavirin in patients with CHC. The anticipated time on study treatment is 1-2 years, and the target sample size is greater than (>) 500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional exclusion criteria concerning ribavirin:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive PEG-IFN (180 microgram \[mcg\]), subcutaneously (sc), once weekly for 24 weeks and Ribavirin 1000-1200 milligram per day (mg/day) (\<75 kilogram (kg); \>75 kg) for 24 weeks.
Drug: Peginterferon alfa-2a · Drug: Ribavirin
Participants will receive PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (\<75kg; \>75 kg) till week 24; if patient is still HCV RNA positive. Treatment will be stopped if participant is HCV RNA negative at week 24 -treatment with PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (\<75kg; \>75 kg) till week 72
Drug: Peginterferon alfa-2a · Drug: Ribavirin
Participants will receive PEG-IFN (180 mcg), sc, once weekly for 48 weeks and Ribavirin 1000-1200 mg/day (\<75kg; \>75 kg) for 48 weeks.
Drug: Peginterferon alfa-2a · Drug: Ribavirin
Participants will receive PEG-IFN (180 mcg), sc, once weekly for 72 weeks and Ribavirin 1000-1200 mg/day (\<75 kg; \> 75 kg) for 72 weeks.
Drug: Peginterferon alfa-2a · Drug: Ribavirin
PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n
Also known as: Pegasys
Ribavirin is available as 200 mg tablets
Percentage of Participants With Relapse Rate in Groups A and B by Genotype at the End of Follow-up (Part 1)
Relapse rate (RR) was defined as the percentage of participants with non-detectable HCV RNA (\< 100 copies/ml) at the end of treatment and detectable HCV RNA at the end of follow-up. End of treatment was defined as Week 48 for Group A and Week 72 for Group B, respectively. The end of follow-up was defined as Week 72 for Group A and Week 96 for Group B, respectively. Relapse rate for treatment Groups A and B, stratified for genotype (Genotype I and Genotype IV) and Week 4 response (\< 600 units/milliliter \[U/ml\] and \>= 600 U/ml) is presented.
Time frame: Up to Week 96
Percentage of Participants Achieving Sustained Virological Response in Groups A1, B1, and E by Genotype at the End of Follow-up (Part 2)
The Sustained Virological Response (SVR) was defined as the percentage of participants in each group with non-detectable HCV RNA result at 24 weeks post completion of the treatment period (HCV RNA \< 15 IU/ml at Week 72 of Groups A1 and E, and at Week 96 of Group B1). Participants without a HCV RNA results at this time point were considered as non-responders. The end of follow-up was defined as Week 72 for Groups A1 and E, and Week 96 for Group B1. The SVR for treatment Groups A1 + B1 and E, stratified for genotype (Genotype I and Genotype IV) is presented.
Time frame: Up to Week 96
Percentage of Participants With Virological Response Rate in Groups A, B, C, and D at the End of Treatment Period (Part 1)
End of treatment response (ETR) rate was defined as the percentage of participants in each group with non-detectable HCV RNA at completion of the treatment period (HCV negative at Week 24 of Group D, Week 48 of Group A and at Week 72 of Groups B and C). Participants without a HCV RNA results at this time point were considered as non-responders. End of the treatment period was defined as Week 48 for Group A, Week 72 for Groups B and C, and Week 24 for Group D.
Time frame: Up to Week 72
Percentage of Participants Achieving Sustained Virological Response in Groups A, B, C, and D at the End of Follow-up (Part 1)
The SVR was defined as the percentage of participants in each group with a non-detectable HCV RNA result at 24 weeks post-completion of the treatment period (HCV RNA \< 15 IU/ml at Week 48 of Group D, at Week 72 of Group A, and at Week 96 of Groups B and C). Participants without a HCV RNA PCR at this time point were considered as non-responders in this calculation. The end of follow-up was defined as Week 72 for Group A, Week 96 for Groups B and C, and Week 48 for Group D.
Time frame: Up to Week 96
Mean Short Form-36 Questionnaire Scores for Groups A and B Over Time (Part 1)
The Short Form-36 (SF-36) is a quality of life instrument consisting of a 36-item questionnaire. The SF-36 items were scored and transformed according to the SF-36 Health Survey Manual and Interpretation Guide. Summary scores for SF-36 dimensions (physical functioning, role functioning, bodily pain, general health, vitality, social functioning, mental health, health transition) as well as physical and mental summary measures were compiled after imputation of mean scores for missing items if more than 50% of dimension-related items were available. Scores for health transition ranged from 0 (worst) to 5 (best). Scores for all other dimensions ranged from 0 (worst) to 100 (best). The mean SF-36 scores are presented at Baseline (Day 1), Week 24, Week 48, Week 72 (for Groups A and B) and at Week 96 (for Group B). Lower score indicate worsening.
Time frame: Baseline (Day 1), Week 24, Week 48, Week 72, and Week 96
Mean Fatigue Severity Scale Scores for Groups A and B Over Time (Part 1)
The Fatigue Severity Scale (FSS) is an instrument consisting of 10 self-administered questions. The FSS items were scored by calculating the average response to all answered items (including the 9 questions and the fatigue symptoms). Each of the 9 questions had answers within a score range of 1-7. A score of 1 for any question indicates less fatigue in everyday life and a score of 7 indicates a higher likelihood of fatigue in everyday life. The mean FSS scores are presented at Baseline (Day 1), Week 24, Week 48 and Week 72 (for Groups A and B) and at Week 96 (for Group B).
Time frame: Baseline (Day 1), Week 24, Week 48 and Week 72, and Week 96
Number of Participants With Fibrosis Grades 0 to 4 at Baseline (Part 1)
Liver fibrosis stage was scored using the METAVIR system (Grade 0 to 4). Grade 0 indicates no fibrosis, Grade 1 indicates stellate enlargement of portal tract but without septa formation, Grade 2 indicates enlargement of portal tract with rare septa formation, Grade 3 indicates numerous septa without cirrhosis and grade 4 indicates cirrhosis. The number of participants with fibrosis grades ranging from 0 to 4 at Baseline is presented.
Time frame: Baseline (Day 1)
Number of Participants With Adverse Events and Serious Adverse Events (Part 1)
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
Time frame: Up to Week 96
Percentage of Participants With Relapse Rates in Groups A1 and B1 at the End of Follow-up (Part 2)
Virological relapse rate was defined as percentage of participants with non-detectable HCV RNA (\< 15 IU/ml) at the EoT and detectable HCV RNA (≥ 15 IU/ml) at the end of FU. The end of treatment was defined as Week 48 in Group A1 and Week 72 in Group B1 and the end of follow-up was defined as Week 72 in Group A1 and Week 96 in Group B1.
Time frame: Up to Week 96
Percentage of Participants With Virological Response Rates in Group A1, B1, C and D at the End of the Treatment Period (Part 2)
ETR virological response rate at the end of treatment period was defined as the percentage of participants in each group with non-detectable HCV RNA at completion of the treatment period (HCV RNA quantitative PCR result \< 15 IU/ml at Week 24 for Group D, at Week 48 for Group A1, at Week 72 for Groups B1 and C). Participants without a HCV RNA PCR (missing values) at this time point were considered as non-responders in this calculation. The end of treatment period was defined as Week 48 for Group A1, Week 72 for Groups B1 and C1, and Week 24 for Group D.
Time frame: Up to Week 72
Percentage of Participants Achieving Sustained Virological Response in Groups C and D by Genotype at the End of Follow-up (Part 2)
The SVR was defined as the percentage of participants in each group with non-detectable HCV RNA result at 24 weeks post completion of the treatment period (HCV RNA \< 15 IU/ml at Week 48 of Group D and at Week 96 of Group C). Participants without a HCV RNA results at this time point were considered as non-responders. The end of follow-up was defined as Week 96 for Group C and Week 48 for Group D.
Time frame: Up to Week 96
Mean Short Form-36 Questionnaire Scores for Groups A1, B1, and C Over Time (Part 2)
The SF-36 is a quality of life instrument consisting of a 36-item questionnaire. The SF-36 items were scored and transformed according to the SF-36 Health Survey Manual \& Interpretation Guide. Summary scores for SF-36 dimensions (physical functioning, role functioning, bodily pain, general health, vitality, social functioning, mental health, health transition) as well as physical and mental summary measures were compiled after imputation of mean scores for missing items if more than 50% of dimension-related items were available. Scores for health transition ranged from 0 (worst) to 5 (best). Scores for all other dimensions ranged from 0 (worst) to 100 (best). The mean SF-36 scores were presented at Baseline (Day 1), Week 24, Week 48, Week 72 (for Groups A1, B1 and C) and at Week 96 (for Groups B1 and C). Lower score indicate worsening.
Time frame: Baseline (Day 1), Week 24, Week 48, Week 72, and Week 96
Mean Fatigue Severity Scale Scores for Groups A1, B1 and C Over Time (Part 2)
The FSS is an instrument consisting of 10 self-administered questions. The FSS items were scored by calculating the average response to all answered items (including the 9 questions and the fatigue symptoms). Each of the 9 questions had answers within a score range of 1-7. A score of 1 for any question indicates less fatigue in everyday life and a score of 7 indicates a higher likelihood of fatigue in everyday life. The mean FSS scores are presented at Baseline (Day 1), Week 24, Week 48 and Week 72 (for Groups A1, B1 and C) and at Week 96 (for Groups B1 and C).
Time frame: Baseline (Day 1), Week 24, Week 48 and Week 72, and Week 96
Number of Participants With Fibrosis Grades 0 to 4 at Baseline (Part 2)
Liver fibrosis stage was based upon biopsy and scored using the METAVIR system (Grade 0 to 4). Grade 0 indicates no fibrosis, Grade 1 indicates stellate enlargement of portal tract but without septa formation, Grade 2 indicates enlargement of portal tract with rare septa formation, Grade 3 indicates numerous septa without cirrhosis and grade 4 indicates cirrhosis. The number of participants with fibrosis grades ranging from 0 to 4 at Baseline (Day 1) is presented.
Time frame: Baseline (Day 1)
Number of Participants With Adverse Events and Serious Adverse Events (Part 2)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
Time frame: Up to Week 96
This study was conducted in 2 parts. Part 1 was conducted from 16 May 2003 to 12 September 2008 at 21 centers in Austria; Part 2 of this study was conducted from 19 October 2009 to 15 November 2013 at 15 centers in Austria.
| Milestone | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1) | PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2) | PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 142 | 152 | 78 | 156 | 17 | 36 | 25 | 20 | 42 | 45 | 8 |
| Completed | 107 | 101 | 7 | 139 | 0 | 20 | 12 | 1 | 36 | 36 | 0 |
| Not completed | 35 | 51 | 71 | 17 | 17 | 16 | 13 | 19 | 6 | 9 | 8 |
| Withdrew: Exclusion criterion during screening | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal of informed consent | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 7 | 8 | 2 | 2 | 5 | 1 | 5 | 0 | 1 | 1 | 5 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 5 | 0 | 0 | 0 |
| Withdrew: Participant unable to attend study visit | 4 | 10 | 1 | 2 | 5 | 1 | 1 | 1 | 0 | 2 | 0 |
| Withdrew: Participant's compliance | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Participant cannot be reached | 4 | 4 | 0 | 8 | 2 | 1 | 0 | 1 | 0 | 2 | 1 |
| Withdrew: Pcr positive at week 24 | 15 | 21 | 62 | 0 | 0 | 6 | 3 | 8 | 0 | 1 | 0 |
| Withdrew: Pcr positive at follow up 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant showed relapse | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Participant stopped study/treatment | 1 | 3 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Therapy stopped due to misunderstanding | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Financial problems | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pcr positive at week 68 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pcr positive at week 48 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pcr not performed at week 12 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: No pcr at baseline | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pcr positive at week 28 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pcr sample for week 4 not drawn | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Inclusion criteria not fulfilled | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Baseline viral load unavailable | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Blood could not be drawn | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Participation in sili rescue study | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Source data not found | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant showed weight reduction | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Non-response week 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: No 2 log drop at week 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Negative pcr result | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Participant's pcr high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant treated after week 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Missing pcr result at week 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Pcr positive | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Relapse rate (RR) was defined as the percentage of participants with non-detectable HCV RNA (\< 100 copies/ml) at the end of treatment and detectable HCV RNA at the end of follow-up. End of treatment was defined as Week 48 for Group A and Week 72 for Group B, respectively. The end of follow-up was defined as Week 72 for Group A and Week 96 for Group B, respectively. Relapse rate for treatment Groups A and B, stratified for genotype (Genotype I and Genotype IV) and Week 4 response (\< 600 units/milliliter \[U/ml\] and \>= 600 U/ml) is presented.
| Percentage of participants | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) |
|---|---|---|
| Genotype I, Week 4 response < 600 U/ml,n= 130, 136 | 22.0 (10.6 to 37.6) | 8.3 (1.8 to 22.5) |
| Genotype I,Week 4 response >=600 U/ml, n =130, 136 | 52.7 (38.8 to 66.3) | 30.0 (17.9 to 44.6) |
| Genotype IV, Week 4 response < 600 U/ml, n =12, 16 | 0.0 (0.0 to 52.2) | 42.9 (9.9 to 81.6) |
| Genotype IV, Week 4 response >=600 U/ml, n =12, 16 | 80.0 (28.4 to 99.5) | 80.0 (28.4 to 99.5) |
The Sustained Virological Response (SVR) was defined as the percentage of participants in each group with non-detectable HCV RNA result at 24 weeks post completion of the treatment period (HCV RNA \< 15 IU/ml at Week 72 of Groups A1 and E, and at Week 96 of Group B1). Participants without a HCV RNA results at this time point were considered as non-responders. The end of follow-up was defined as Week 72 for Groups A1 and E, and Week 96 for Group B1. The SVR for treatment Groups A1 + B1 and E, stratified for genotype (Genotype I and Genotype IV) is presented.
| Percentage of participants | PEG-IFN Alfa 2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa 2a + Ribavirin 72 Weeks (Group B1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2) |
|---|---|---|---|
| Genotype I, n = 33, 23, 39 | 30.3 (15.6 to 48.7) | 34.8 (16.4 to 57.3) | 64.1 (47.2 to 78.8) |
| Genotype IV, n = 3, 2, 6 | 33.3 (0.8 to 90.6) | 0.0 (0.0 to 84.2) | 50.0 (11.8 to 88.2) |
End of treatment response (ETR) rate was defined as the percentage of participants in each group with non-detectable HCV RNA at completion of the treatment period (HCV negative at Week 24 of Group D, Week 48 of Group A and at Week 72 of Groups B and C). Participants without a HCV RNA results at this time point were considered as non-responders. End of the treatment period was defined as Week 48 for Group A, Week 72 for Groups B and C, and Week 24 for Group D.
| Percentage of participants | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1) |
|---|---|---|---|---|
| Percentage of Participants With Virological Response Rate in Groups A, B, C, and D at the End of Treatment Period (Part 1) | 74.6 (66.7 to 81.6) | 64.5 (56.3 to 72.1) | 9.0 (3.7 to 17.6) | 92.3 (86.9 to 96.0) |
The SVR was defined as the percentage of participants in each group with a non-detectable HCV RNA result at 24 weeks post-completion of the treatment period (HCV RNA \< 15 IU/ml at Week 48 of Group D, at Week 72 of Group A, and at Week 96 of Groups B and C). Participants without a HCV RNA PCR at this time point were considered as non-responders in this calculation. The end of follow-up was defined as Week 72 for Group A, Week 96 for Groups B and C, and Week 48 for Group D.
| Percentage of participants | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1) |
|---|---|---|---|---|
| Percentage of Participants Achieving Sustained Virological Response in Groups A, B, C, and D at the End of Follow-up (Part 1) | 45.1 (36.7 to 53.6) | 48.0 (39.9 to 56.3) | 6.4 (2.1 to 14.3) | 73.7 (66.1 to 80.4) |
The Short Form-36 (SF-36) is a quality of life instrument consisting of a 36-item questionnaire. The SF-36 items were scored and transformed according to the SF-36 Health Survey Manual and Interpretation Guide. Summary scores for SF-36 dimensions (physical functioning, role functioning, bodily pain, general health, vitality, social functioning, mental health, health transition) as well as physical and mental summary measures were compiled after imputation of mean scores for missing items if more than 50% of dimension-related items were available. Scores for health transition ranged from 0 (worst) to 5 (best). Scores for all other dimensions ranged from 0 (worst) to 100 (best). The mean SF-36 scores are presented at Baseline (Day 1), Week 24, Week 48, Week 72 (for Groups A and B) and at Week 96 (for Group B). Lower score indicate worsening.
| scores on a scale | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) |
|---|---|---|
| Physical Functioning, Baseline, n = 106, 121 | 86.9 ± 15.1 | 87.0 ± 17.8 |
| Physical Functioning, Week 24, n = 77, 90 | 61.8 ± 28.2 | 69.2 ± 22.6 |
| Physical Functioning, Week 48, n = 67, 77 | 66.1 ± 26.2 | 66.8 ± 23.1 |
| Physical Functioning, Week 72, n = 65, 68 | 89.8 ± 14.1 | 70.3 ± 24.6 |
| Physical Functioning, Week 96, n = 0, 59 | NA ± NA | 87.0 ± 20.4 |
| Role Functioning - Physical, Baseline,n = 105, 120 | 74.7 ± 36.3 | 76.2 ± 36.9 |
| Role Functioning - Physical, Week 24, n = 77, 88 | 39.0 ± 43.0 | 45.7 ± 41.9 |
| Role Functioning - Physical, Week 48, n = 66, 76 | 40.7 ± 39.9 | 42.2 ± 44.0 |
| Role Functioning - Physical, Week 72, n = 65, 67 | 81.5 ± 32.9 | 47.4 ± 43.5 |
| Role Functioning - Physical, Week 96, n = 0, 58 | NA ± NA | 84.5 ± 29.9 |
| Bodily Pain, Baseline, n = 103, 120 | 82.3 ± 22.5 | 83.5 ± 22.9 |
| Bodily Pain, Week 24, n = 76, 91 | 68.2 ± 31.1 | 70.0 ± 29.6 |
| Bodily Pain, Week 48, n = 67, 77 | 69.5 ± 28.6 | 66.8 ± 30.6 |
| Bodily Pain, Week 72, n = 64, 70 | 85.4 ± 23.2 | 67.3 ± 29.3 |
| Bodily Pain, Week 96, n = 0, 61 | NA ± NA | 90.2 ± 19.8 |
| General Health, Baseline, n = 102, 119 | 64.5 ± 17.9 | 66.3 ± 19.7 |
| General Health, Week 24, n = 75, 83 | 58.9 ± 19.0 | 55.1 ± 22.8 |
| General Health, Week 48, n = 63, 74 | 58.1 ± 20.2 | 56.3 ± 19.2 |
| General Health, Week 72, n = 65, 62 | 71.7 ± 18.8 | 60.1 ± 19.3 |
| General Health, Week 96, n = 0, 59 | NA ± NA | 70.3 ± 18.5 |
| Vitality, Baseline, n = 103, 116 | 56.8 ± 20.9 | 58.9 ± 22.5 |
| Vitality, Week 24, n = 75, 88 | 40.3 ± 24.0 | 40.6 ± 23.6 |
| Vitality, Week 48, n = 66, 77 | 40.6 ± 23.8 | 41.2 ± 21.2 |
| Vitality, Week 72, n = 63, 67 | 66.9 ± 18.9 | 43.5 ± 22.4 |
| Vitality, Week 96, n = 0, 59 | NA ± NA | 62.9 ± 21.1 |
| Social Functioning, Baseline, n = 105, 121 | 79.8 ± 21.9 | 81.6 ± 22.0 |
| Social Functioning, Week 24, n = 77, 91 | 64.4 ± 28.5 | 64.1 ± 30.3 |
| Social Functioning, Week 48, n = 67, 78 | 71.6 ± 24.0 | 57.2 ± 27.5 |
| Social Functioning, Week 72, n = 65, 70 | 86.3 ± 22.3 | 63.8 ± 29.4 |
| Social Functioning, Week 96, n = 0, 61 | NA ± NA | 83.4 ± 23.4 |
| Role Functioning - Emotional,Baseline,n = 104, 120 | 71.5 ± 39.3 | 75.8 ± 36.6 |
| Role Functioning - Emotional, Week 24, n = 76, 88 | 36.8 ± 42.4 | 43.9 ± 43.3 |
| Role Functioning - Emotional, Week 48, n = 66, 74 | 41.7 ± 41.0 | 42.8 ± 42.9 |
| Role Functioning - Emotional, Week 72, n = 65, 66 | 80.5 ± 32.8 | 43.4 ± 43.4 |
| Role Functioning - Emotional, Week 96, n = 0, 58 | NA ± NA | 84.5 ± 31.4 |
| Mental Health, Baseline, n = 103, 115 | 69.6 ± 18.7 | 71.9 ± 19.1 |
| Mental Health, Week 24, n = 76, 88 | 60.7 ± 19.3 | 57.9 ± 21.5 |
| Mental Health, Week 48, n = 66, 77 | 62.6 ± 19.8 | 59.6 ± 20.7 |
| Mental Health, Week 72, n = 63, 67 | 76.3 ± 16.2 | 60.8 ± 18.5 |
| Mental Health, Week 96, n = 0, 59 | NA ± NA | 72.3 ± 14.6 |
| Reported Health Transition, Baseline, n = 105, 123 | 3.1 ± 0.9 | 3.0 ± 0.9 |
| Reported Health Transition, Week 24, n = 77, 90 | 3.5 ± 1.2 | 3.2 ± 1.2 |
| Reported Health Transition, Week 48, n = 67, 77 | 3.2 ± 1.3 | 3.0 ± 1.3 |
| Reported Health Transition, Week 72, n = 65, 69 | 1.6 ± 0.9 | 2.3 ± 1.1 |
| Reported Health Transition, Week 96, n = 0, 61 | NA ± NA | 1.3 ± 0.7 |
The Fatigue Severity Scale (FSS) is an instrument consisting of 10 self-administered questions. The FSS items were scored by calculating the average response to all answered items (including the 9 questions and the fatigue symptoms). Each of the 9 questions had answers within a score range of 1-7. A score of 1 for any question indicates less fatigue in everyday life and a score of 7 indicates a higher likelihood of fatigue in everyday life. The mean FSS scores are presented at Baseline (Day 1), Week 24, Week 48 and Week 72 (for Groups A and B) and at Week 96 (for Group B).
| scores on a scale | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) |
|---|---|---|
| Baseline, n = 104, 114 | 3.6 ± 1.5 | 3.4 ± 1.7 |
| Week 24, n = 69, 77 | 4.5 ± 1.7 | 4.7 ± 1.7 |
| Week 48, n = 59, 63 | 4.7 ± 1.6 | 4.7 ± 1.5 |
| Week 72, n = 58, 62 | 3.0 ± 1.5 | 4.3 ± 1.8 |
| Week 96, n = 0, 57 | NA ± NA | 3.4 ± 1.5 |
Liver fibrosis stage was scored using the METAVIR system (Grade 0 to 4). Grade 0 indicates no fibrosis, Grade 1 indicates stellate enlargement of portal tract but without septa formation, Grade 2 indicates enlargement of portal tract with rare septa formation, Grade 3 indicates numerous septa without cirrhosis and grade 4 indicates cirrhosis. The number of participants with fibrosis grades ranging from 0 to 4 at Baseline is presented.
| Number of participants | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1) | PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1) |
|---|---|---|---|---|---|
| Grade 0 | 11 | 15 | 8 | 17 | 1 |
| Grade 1 | 38 | 40 | 20 | 57 | 1 |
| Grade 2 | 64 | 68 | 23 | 58 | 6 |
| Grade 3 | 18 | 13 | 15 | 10 | 3 |
| Grade 4 | 11 | 16 | 11 | 14 | 0 |
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
| Number of participants | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1) | PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1) |
|---|---|---|---|---|---|
| Number of participants with any AE | 140 | 149 | 76 | 153 | 10 |
| Number of participants with any SAE | 22 | 28 | 8 | 14 | 2 |
Virological relapse rate was defined as percentage of participants with non-detectable HCV RNA (\< 15 IU/ml) at the EoT and detectable HCV RNA (≥ 15 IU/ml) at the end of FU. The end of treatment was defined as Week 48 in Group A1 and Week 72 in Group B1 and the end of follow-up was defined as Week 72 in Group A1 and Week 96 in Group B1.
| Percentage of participants | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) |
|---|---|---|
| Percentage of Participants With Relapse Rates in Groups A1 and B1 at the End of Follow-up (Part 2) | 41.2 (18.4 to 67.1) | 38.5 (13.9 to 68.4) |
ETR virological response rate at the end of treatment period was defined as the percentage of participants in each group with non-detectable HCV RNA at completion of the treatment period (HCV RNA quantitative PCR result \< 15 IU/ml at Week 24 for Group D, at Week 48 for Group A1, at Week 72 for Groups B1 and C). Participants without a HCV RNA PCR (missing values) at this time point were considered as non-responders in this calculation. The end of treatment period was defined as Week 48 for Group A1, Week 72 for Groups B1 and C1, and Week 24 for Group D.
| Percentage of participants | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2) |
|---|---|---|---|---|
| Percentage of Participants With Virological Response Rates in Group A1, B1, C and D at the End of the Treatment Period (Part 2) | 47.2 (30.4 to 64.5) | 52.0 (31.3 to 72.2) | 5.0 (0.1 to 24.9) | 90.5 (77.4 to 97.3) |
The SVR was defined as the percentage of participants in each group with non-detectable HCV RNA result at 24 weeks post completion of the treatment period (HCV RNA \< 15 IU/ml at Week 48 of Group D and at Week 96 of Group C). Participants without a HCV RNA results at this time point were considered as non-responders. The end of follow-up was defined as Week 96 for Group C and Week 48 for Group D.
| Percentage of participants | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2) |
|---|---|---|
| Percentage of Participants Achieving Sustained Virological Response in Groups C and D by Genotype at the End of Follow-up (Part 2) | 0.0 (0.0 to 16.8) | 73.8 (58.0 to 86.1) |
The SF-36 is a quality of life instrument consisting of a 36-item questionnaire. The SF-36 items were scored and transformed according to the SF-36 Health Survey Manual \& Interpretation Guide. Summary scores for SF-36 dimensions (physical functioning, role functioning, bodily pain, general health, vitality, social functioning, mental health, health transition) as well as physical and mental summary measures were compiled after imputation of mean scores for missing items if more than 50% of dimension-related items were available. Scores for health transition ranged from 0 (worst) to 5 (best). Scores for all other dimensions ranged from 0 (worst) to 100 (best). The mean SF-36 scores were presented at Baseline (Day 1), Week 24, Week 48, Week 72 (for Groups A1, B1 and C) and at Week 96 (for Groups B1 and C). Lower score indicate worsening.
| scores on a scale | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) |
|---|---|---|---|
| Physical functioning, Baseline, n = 22, 18, 15 | 82.5 ± 22.5 | 83.1 ± 17.7 | 78.5 ± 28.8 |
| Physical functioning, Week 24, n = 17, 13, 9 | 61.8 ± 25.8 | 51.2 ± 25.2 | 72.2 ± 24.9 |
| Physical functioning, Week 48, n = 13, 8, 0 | 66.5 ± 22.8 | 76.3 ± 19.8 | NA ± NA |
| Physical functioning, Week 72, n = 10, 7, 1 | 77.0 ± 18.4 | 80.7 ± 9.3 | 45.0 ± NA |
| Physical functioning, Week 96, n = 0, 6, 0 | NA ± NA | 85.8 ± 17.7 | NA ± NA |
| Role Functioning- Physical, Baseline,n =22, 18, 15 | 75.0 ± 33.6 | 62.0 ± 42.1 | 53.3 ± 41.0 |
| Role Functioning - Physical, Week 24, n= 17, 13, 8 | 41.2 ± 44.1 | 15.4 ± 33.1 | 43.8 ± 43.8 |
| Role Functioning - Physical, Week 48, n = 13, 8, 0 | 41.0 ± 41.3 | 56.3 ± 39.5 | NA ± NA |
| Role Functioning - Physical,, Week 72, n= 10, 7,1 | 60.0 ± 47.4 | 82.1 ± 37.4 | 0.0 ± 0.0 |
| Role Functioning - Physical, Week 96, n = 0, 5, 0 | NA ± NA | 70.0 ± 32.6 | NA ± NA |
| Bodily Pain, Baseline, n = 21, 19, 15 | 75.3 ± 26.7 | 76.3 ± 25.5 | 66.5 ± 31.7 |
| Bodily Pain, Week 24, n = 17, 13, 8 | 57.9 ± 28.5 | 45.9 ± 27.9 | 54.9 ± 17.8 |
| Bodily Pain, Week 48, n = 13, 8, 0 | 66.4 ± 31.6 | 54.6 ± 19.2 | NA ± NA |
| Bodily Pain, Week 72, n = 10, 7, 1 | 71.1 ± 30.1 | 70.4 ± 15.0 | 62.0 ± NA |
| Bodily Pain, Week 96, n = 0, 6, 0 | NA ± NA | 74.5 ± 19.3 | NA ± NA |
| General Health, Baseline, n = 22, 16, 14 | 61.8 ± 18.8 | 56.7 ± 21.7 | 53.4 ± 19.1 |
| General Health, Week 24, n = 17, 11, 8 | 52.8 ± 23.6 | 37.1 ± 14.1 | 57.1 ± 24.4 |
| General Health, Week 48, n = 12, 8, 0 | 54.4 ± 21.0 | 56.3 ± 23.8 | NA ± NA |
| General Health, Week 72, n = 10, 7, 1 | 55.0 ± 21.8 | 59.9 ± 16.5 | 35.0 ± NA |
| General Health, Week 96, n = 0, 6, 0 | NA ± NA | 52.8 ± 18.8 | NA ± NA |
| Vitality, Baseline, n = 21, 18, 15 | 54.0 ± 21.9 | 52.5 ± 19.3 | 45.0 ± 16.0 |
| Vitality, Week 24, n = 17, 11, 8 | 37.8 ± 13.9 | 31.2 ± 21.7 | 43.1 ± 17.9 |
| Vitality, Week 48, n = 13, 8, 0 | 43.2 ± 22.1 | 48.1 ± 17.3 | NA ± NA |
| Vitality, Week 72, n = 9, 7, 1 | 47.2 ± 23.1 | 60.2 ± 16.7 | 40.0 ± NA |
| Vitality, Week 96, n = 0, 6, 0 | NA ± NA | 56.9 ± 15.1 | NA ± NA |
| Social Functioning, Baseline, n = 22, 19, 15 | 84.7 ± 18.5 | 78.9 ± 25.0 | 72.5 ± 33.5 |
| Social Functioning, Week 24, n = 17, 13, 8 | 64.7 ± 26.6 | 56.7 ± 23.2 | 65.6 ± 23.9 |
| Social Functioning, Week 48, n = 13, 8, 0 | 62.5 ± 27.5 | 78.1 ± 27.3 | NA ± NA |
| Social Functioning, Week 72, n = 10, 7, 1 | 77.5 ± 20.2 | 78.6 ± 15.7 | 25.0 ± NA |
| Social Functioning, Week 96, n = 0, 6, 0 | NA ± NA | 83.3 ± 17.1 | NA ± NA |
| Role Functioning -Emotional,Baseline,n =22, 18, 15 | 71.2 ± 38.9 | 62.0 ± 42.7 | 53.3 ± 45.1 |
| Role Functioning-Emotional, Week 24, n=17, 13, 8 | 43.1 ± 43.7 | 20.5 ± 37.4 | 45.8 ± 50.2 |
| Role Functioning - Emotional, Week 48, n= 13, 8, 0 | 43.6 ± 39.4 | 54.2 ± 46.9 | NA ± NA |
| Role Functioning - Emotional, Week 72, n= 10, 7, 1 | 56.7 ± 49.8 | 81.0 ± 37.8 | 0.0 ± 0.0 |
| Role Functioning - Emotional, Week 96, n = 0, 5, 0 | NA ± NA | 60.0 ± 43.5 | NA ± NA |
| Mental Health, Baseline, n = 21, 18, 15 | 71.6 ± 18.1 | 62.9 ± 22.0 | 62.1 ± 20.8 |
| Mental Health, Week 24, n = 17, 11, 8 | 58.8 ± 21.5 | 46.2 ± 18.6 | 62.0 ± 19.9 |
| Mental Health, Week 48, n = 13, 8, 0 | 57.4 ± 24.0 | 61.0 ± 16.8 | NA ± NA |
| Mental Health, Week 72, n = 9, 7, 1 | 66.7 ± 24.0 | 66.9 ± 17.8 | 36.0 ± NA |
| Mental Health, Week 96, n = 0, 6, 0 | NA ± NA | 58.3 ± 15.1 | NA ± NA |
| Reported Health Transition,Baseline, n =22, 19, 15 | 3.0 ± 1.1 | 2.9 ± 0.9 | 3.3 ± 1.0 |
| Reported Health Transition, Week 24, 17, 13, 9 | 3.8 ± 1.0 | 3.5 ± 1.2 | 3.2 ± 1.1 |
| Reported Health Transition, Week 48, n = 13, 8, 0 | 2.9 ± 1.1 | 2.9 ± 1.1 | NA ± NA |
| Reported Health Transition, Week 72, n = 10, 7, 1 | 2.8 ± 1.2 | 2.6 ± 1.3 | 4.0 ± NA |
| Reported Health Transition, Week 96, n = 0, 6, 0 | NA ± NA | 2.0 ± 0.9 | NA ± NA |
The FSS is an instrument consisting of 10 self-administered questions. The FSS items were scored by calculating the average response to all answered items (including the 9 questions and the fatigue symptoms). Each of the 9 questions had answers within a score range of 1-7. A score of 1 for any question indicates less fatigue in everyday life and a score of 7 indicates a higher likelihood of fatigue in everyday life. The mean FSS scores are presented at Baseline (Day 1), Week 24, Week 48 and Week 72 (for Groups A1, B1 and C) and at Week 96 (for Groups B1 and C).
| scores on a scale | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) |
|---|---|---|---|
| Baseline, n = 22, 17, 15 | 3.7 ± 1.6 | 3.8 ± 2.0 | 3.9 ± 1.9 |
| Week 24, n = 17, 15, 9 | 4.2 ± 1.7 | 4.9 ± 1.6 | 4.8 ± 1.6 |
| Week 48, n = 11, 7, 0 | 4.0 ± 1.5 | 4.5 ± 1.3 | NA ± NA |
| Week 72, n = 8, 7, 1 | 3.9 ± 1.9 | 3.8 ± 2.2 | 5.3 ± NA |
| Week 96, n = 0, 7, 0 | NA ± NA | 4.5 ± 1.9 | NA ± NA |
Liver fibrosis stage was based upon biopsy and scored using the METAVIR system (Grade 0 to 4). Grade 0 indicates no fibrosis, Grade 1 indicates stellate enlargement of portal tract but without septa formation, Grade 2 indicates enlargement of portal tract with rare septa formation, Grade 3 indicates numerous septa without cirrhosis and grade 4 indicates cirrhosis. The number of participants with fibrosis grades ranging from 0 to 4 at Baseline (Day 1) is presented.
| Number of participants | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2) |
|---|---|---|---|---|---|
| Grade 0 | 5 | 4 | 1 | 4 | 3 |
| Grade 1 | 6 | 3 | 2 | 8 | 9 |
| Grade 2 | 4 | 4 | 6 | 10 | 8 |
| Grade 3 | 5 | 2 | 5 | 1 | 1 |
| Grade 4 | 5 | 4 | 1 | 0 | 5 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
| Number of participants | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2) | PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2) |
|---|---|---|---|---|---|---|
| Number of participants with any AE | 36 | 25 | 19 | 40 | 43 | 7 |
| Number of participants with any SAE | 1 | 3 | 2 | 5 | 7 | 1 |
Collected over Up to Week 96. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | — | 22/142 (15.5%) | 139/142 (97.9%) |
| PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) | — | 28/152 (18.4%) | 147/152 (96.7%) |
| PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1) | — | 8/78 (10.3%) | 76/78 (97.4%) |
| PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1) | — | 14/156 (9%) | 150/156 (96.2%) |
| PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1) | — | 2/12 (16.7%) | 9/12 (75%) |
| PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | — | 1/36 (2.8%) | 36/36 (100%) |
| PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) | — | 3/25 (12%) | 25/25 (100%) |
| PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) | — | 2/20 (10%) | 19/20 (95%) |
| PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2) | — | 5/42 (11.9%) | 40/42 (95.2%) |
| PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2) | — | 7/45 (15.6%) | 42/45 (93.3%) |
| PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2) | — | 1/8 (12.5%) | 6/8 (75%) |
| Event | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1) | PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2) | PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 2/142 | 1/152 | 0/78 | 0/156 | 0/12 | 0/36 | 0/25 | 0/20 | 0/42 | 0/45 | 1/8 |
| Circulatory collapseVascular disorders | 0/142 | 0/152 | 0/78 | 0/156 | 1/12 | 0/36 | 0/25 | 0/20 | 0/42 | 0/45 | 0/8 |
| Ovarian CystReproductive system and breast disorders | 0/142 | 0/152 | 0/78 | 0/156 | 1/12 | 0/36 | 0/25 | 0/20 | 0/42 | 0/45 | 0/8 |
| Ovarian NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/142 | 0/152 | 0/78 | 0/156 | 1/12 | 0/36 | 0/25 | 0/20 | 0/42 | 0/45 | 0/8 |
| Abdominal pain lowerGastrointestinal disorders | 0/142 | 0/152 | 0/78 | 0/156 | 0/12 | 0/36 | 0/25 | 1/20 | 0/42 | 0/45 | 0/8 |
| Jaundice CholestaticHepatobiliary disorders | 0/142 | 0/152 | 0/78 | 0/156 | 0/12 | 0/36 | 0/25 | 1/20 | 0/42 | 0/45 | 0/8 |
| AnaemiaBlood and lymphatic system disorders | 0/142 | 2/152 | 0/78 | 1/156 | 0/12 | 0/36 | 0/25 | 0/20 | 0/42 | 2/45 | 0/8 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/142 | 0/152 | 0/78 | 2/156 | 0/12 | 0/36 | 0/25 | 0/20 | 1/42 | 2/45 | 0/8 |
| CryoglobulinaemiaVascular disorders | 0/142 | 0/152 | 0/78 | 0/156 | 0/12 | 0/36 | 1/25 | 0/20 | 0/42 | 0/45 | 0/8 |
| Renal FailureRenal and urinary disorders | 0/142 | 0/152 | 0/78 | 0/156 | 0/12 | 0/36 | 1/25 | 0/20 | 0/42 | 0/45 | 0/8 |
| Event | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1) | PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2) | PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 86/142 | 94/152 | 35/78 | 72/156 | 4/12 | 20/36 | 14/25 | 11/20 | 21/42 | 30/45 | 1/8 |
| Influenza Like IllnessGeneral disorders | 60/142 | 57/152 | 41/78 | 61/156 | 5/12 | 15/36 | 14/25 | 7/20 | 13/42 | 14/45 | 1/8 |
| HeadacheNervous system disorders | 42/142 | 38/152 | 10/78 | 26/156 | 1/12 | 8/36 | 3/25 | 5/20 | 8/42 | 10/45 | 1/8 |
| DepressionPsychiatric disorders | 30/142 | 44/152 | 20/78 | 27/156 | 0/12 | 7/36 | 1/25 | 1/20 | 5/42 | 7/45 | 1/8 |
| PruritusSkin and subcutaneous tissue disorders | 36/142 | 27/152 | 19/78 | 18/156 | 2/12 | 6/36 | 5/25 | 3/20 | 8/42 | 13/45 | 1/8 |
| RashSkin and subcutaneous tissue disorders | 35/142 | 39/152 | 15/78 | 24/156 | 2/12 | 6/36 | 7/25 | 1/20 | 5/42 | 7/45 | 1/8 |
| NauseaGastrointestinal disorders | 27/142 | 22/152 | 11/78 | 15/156 | 0/12 | 10/36 | 3/25 | 2/20 | 7/42 | 7/45 | 1/8 |
| Decreased AppetiteMetabolism and nutrition disorders | 16/142 | 26/152 | 6/78 | 22/156 | 0/12 | 10/36 | 3/25 | 3/20 | 4/42 | 4/45 | 1/8 |
| AlopeciaSkin and subcutaneous tissue disorders | 29/142 | 39/152 | 8/78 | 27/156 | 0/12 | 4/36 | 3/25 | 1/20 | 7/42 | 7/45 | 0/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 26/142 | 25/152 | 10/78 | 13/156 | 3/12 | 4/36 | 2/25 | 0/20 | 3/42 | 3/45 | 1/8 |
Baseline characteristics are presented for the safety population which included all participants who received at least on dose of (either) study drug and had at least one post-baseline safety assessment.
| Age, Continuous(years) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1) | PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2) | PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 45.0 ± 10.7 | 44.2 ± 10.2 | 46.6 ± 9.0 | 40.5 ± 11.7 | 46.5 ± 9.5 | 44.6 ± 9.1 | 47.3 ± 9.8 | 46.6 ± 8.7 | 37.8 ± 11.1 | 41.1 ± 10.2 | 43.6 ± 15.4 | 43.5 ± 10.78 |
| Sex: Female, Male(Participants) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 1) | PEG-IFN Alfa-2a + Ribavirin (Not Randomized) (Part 1) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group A1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 72 Weeks (Group B1) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24/72 Weeks (Group C) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 24 Weeks (Group D) (Part 2) | PEG-IFN Alfa-2a + Ribavirin 48 Weeks (Group E) (Part 2) | PEG-IFN Alfa-2a + Ribavirin (Not Assigned) (Part 2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 50 | 53 | 21 | 57 | 4 | 8 | 8 | 5 | 17 | 20 | 3 | 246 |
| Male | 92 | 99 | 57 | 99 | 8 | 28 | 17 | 15 | 25 | 25 | 5 | 470 |
The record gives a start of May 2003, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin